Merck seeks FDA and EMA approvals for V114 pneumococcal conjugate vaccine candidate

By on    Pharma Industry News  

Merck seeks FDA and EMA approvals for V114 pneumococcal conjugate vaccine candidate

V114 pneumococcal conjugate vaccine candidate : Merck has submitted applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval for V114, its 15-valent pneumococcal conjugate vaccine candidate. The Merck vaccine candidate is intended for use in adults 18 years of age and older. The pharma giant said that it […]

FDA approves Eisai and Merck’s Lenvima for first-line treatment of liver cancer

By on    Pharma Industry News  

FDA approves Eisai and Merck’s Lenvima for first-line treatment of liver cancer

In a significant development for cancer treatment, Eisai and Merck have announced that the U.S. Food and Drug Administration (FDA) has approved Lenvima (lenvatinib) for the first-line treatment of hepatocellular carcinoma (HCC), the most common type of primary liver cancer in adults. This approval marks a pivotal advance, offering a new treatment option for patients […]